The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.

ABSTRACT: Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or predictive biomarkers that can enhance our ability to forecast clinical outcomes. To date, most studies involving MRI in CHR are likely not sufficiently powered to generate robust and generalizable neuroimaging results. Here, we describe the prospective, advanced, and modern neuroimaging protocol that was implemented in a complex multi-site, multi-vendor environment, as part of the large-scale Accelerating Medicines Partnership® Schizophrenia Program (AMP® SCZ), including the rationale for various choices. This protocol includes T1- and T2-we

SUBMITTER: Harms MP 

PROVIDER: S-EPMC11965426 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature